Super humanized antibodies

• US 7,732,578 B2
• Filed: 02/08/2005
• Issued: 06/08/2010
• Est. Priority Date: 07/12/2001
• Status: Expired due to Term

• Current Assignee: Arrowsmith Technology Licensing LLC
• Original Assignee: Arrowsmith Technology Licensing LLC
• Inventors: Foote, Jefferson
• Primary Examiner(s): Blanchard; David J.
• Application Number:
  US11/054,669
• Publication Number:
  US 20050261480A1
• Time in Patent Office: 1,946 Days
• Field of Search: None
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 16/464 Igs containing CDR-residues from one specie grafted between FR-residues from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/567 Framework region [FR]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.

Claims

1. A humanized antibody or a binding fragment thereof comprising:

a humanized heavy chain variable region containing three CDR sequences from a heavy chain variable region of a subject non-human antibody grafted into a variable region framework of a candidate human germline heavy chain variable region sequence and comprises two human CDR sequences with the same canonical structure type as the non-human CDR sequences in the subject non-human antibody for two corresponding CDR positions, provided that residues 61-65 of CDR2 of the humanized heavy chain variable region are residues from positions 61-65 from the candidate human germline heavy chain variable region sequence; and

a humanized light chain variable region containing three CDR sequences from a light chain variable region of the subject antibody grafted into a variable region framework of a candidate human germline light chain variable region sequence and comprises three human CDR sequences with the same canonical structure type as non-human CDR sequences from the subject non-human antibody for three corresponding CDR positions;

wherein the humanized antibody or a binding fragment thereof selected from a Fab fragment, a (Fab)′

2 molecule, and a single chain Fv molecule binds to the same antigen as the subject non-human antibody

wherein the CDR boundaries and numbering of residues of the humanized antibody are as defined by Kabat.

2. A humanized antibody or binding fragment thereof comprising:

a humanized heavy chain variable region containing three non-human CDR sequences from a non-human heavy chain variable region from a subject non-human antibody grafted into a heavy chain variable region framework sequence that is characterized by having no more than 10 amino acid residues that differ from a framework sequence of a candidate human germline antibody heavy chain variable region sequence and comprises two human CDR sequences with the same canonical structure type as the non-human CDR sequences from the heavy chain variable region of the subject non-human antibody for the two corresponding CDR positions provided that residues 61-65 of CDR2 of the humanized heavy chain variable region are residues from positions 61-65 from the candidate human germline heavy chain variable region sequence; and

a humanized antibody light chain variable region containing three non-human CDR sequences from a non-human light chain variable region of the subject non-human antibody grafted into a light chain variable region framework sequence that is characterized by having no more than 10 amino acid residues that differ from a framework sequence of a candidate human germline antibody light chain variable region sequence and comprises two human CDR sequences with the same canonical structure type as the non-human CDR sequences from the light chain variable region of the subject non-human antibody for the two corresponding CDR positions,

wherein the humanized antibody or a binding fragment thereof selected from a Fab fragment, a (Fab)′

2 molecule, and a single chain Fv molecule binds to the same anantigen as the subject non-human antibody;

wherein the CDR boundaries and numbering of residues of the humanized antibody are as defined by Kabat.

3. The humanized antibody or binding fragment of claim 2, wherein the subject non-human antibody is a mouse antibody.

4. The humanized antibody or binding fragment thereof of claim 2 in the form of a molecule selected from the group consisting of a Fab fragment, a (Fab)′

₂ molecule, and a single chain Fv molecule.

5. The humanized antibody or binding fragment of claim 2, further comprising a human antibody constant region.

6. The humanized antibody or binding fragment of claim 2 that has an association constant for its antigen of at least 10⁶ M⁻

1, at least 10⁷ M<sup>−

1</sup> or at least 10⁸ M<sup>−

1</sup>.

7. The humanized antibody or binding fragment of claim 2 that does not elicit an immune response when administered to a human.

8. The humanized antibody or binding fragment of claim 2 that binds a human CD28 antigen.

9. The humanized antibody or binding fragment of claim 2, wherein the heavy chain variable region framework sequence has no more than 2 amino acid residues that differ from the framework sequence of the candidate human antibody heavy chain variable region sequence.

10. The humanized antibody or binding fragment of claim 2,

with the proviso that if one of the three non-human light chain CDR sequences does not have the same canonical structure type as the human CDR sequence for the corresponding CDR position of the one CDR, then the differing canonical structure type of the candidate human variable region has a length no more than two amino acid residues smaller or larger than the non-human canonical structure type at the corresponding position.

11. The humanized antibody or binding fragment of claim 10, wherein:

if the one non-human light chain CDR sequence not having the same canonical structure type as the corresponding human CDR is of canonical type 1, then the candidate human variable region has a canonical type 2 CDR at the corresponding position;

or

if the one non-human CDR sequence is of canonical type 5, then the candidate human variable region has a canonical type 4 or 3 CDR at the corresponding position.

12. The humanized antibody or binding fragment of claim 2, wherein the candidate human antibody germline light chain variable region sequence comprises three human CDR sequences with the same canonical structure type as the non-human CDR sequences for the three corresponding CDR positions.